Psoriatic Arthritis

According to a poster presented at CCR East 2020, patients <60 and ≥60 years old achieved minimal disease activity and cDAPSA low disease or remission.

Treat-to-target strategies can be effective in addressing rheumatic diseases like psoriatic arthritis, but may not be enough on their own to single-handedly improve quality of life for those living with the disease, write physicians in a new article in Arthritis and Rheumatology.

Researchers writing in Arthritis Care and Research this week report that rheumatoid arthritis patients actually have a lower rate of type 2 diabetes than people without RA or patients with hypertension, osteoarthritis and psoriatic arthritis.

Guselkumab represents the first FDA approved medication for active psoriatic arthritis that selectively inhibits interleukin-23.

The U.S. Food and Drug Administration has approved the first IL-23 inhibitor for moderate to severe psoriatic arthritis. The newly approved treatment, guselkumab, has been shown to improve the signs and symptoms of fatigue associated with PsA.

Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.

Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.

The safety profile is consistent with previous studies of the ixekizumab.

Remission and LDA rates generally increased over time in patients with psoriatic arthritis receiving tofacitinib.

The late-breaking data reveal the safety and efficacy of upadacitinib versus placebo and adalimumab.

The findings are based on data from a 24-week observation from an ongoing phase 3 PATERA study.

In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.

Patients report sustained improvements in pain and fatigue from taking ixekizumab every 2 or 4 weeks over 3 years.

Eli Lilly announced this week that Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA). And, this week during the EULAR annual meeting, the company is reporting results from the 52-week SPIRIT phase 3b/4 trial for psoriatic arthritis comparing ixekizumab to adalimumab.

In both DISCOVER trials, investigators find guselkumab effective against active psoriatic arthritis domains.

Physicians from New York University Langone Health report in the New England Journal of Medicine that the baseline use of biologics was not associated with worse outcomes in a group of 14 patients with autoimmune disease who contracted COVID-19.

Can a patient with hidradenitis suppurativa develop rheumatoid arthritis? Apparently so, according to researchers writing in JAMA Dermatology this month.